7 citations
,
January 2023 in “Journal of Hematology & Oncology” This review discusses how targeting protein degradation processes may help overcome cancer drug resistance, but reports no new clinical results and suggests further research for precise therapeutic strategies.
8 citations
,
November 2025 in “Journal of Translational Medicine” This review highlights challenges in developing drugs targeting the Wnt/β-Catenin signaling pathway for cancer due to its complexity and essential roles in normal tissue. It explores targeted protein degradation technology as a promising strategy to overcome these challenges, suggesting potential new avenues for drug development.
August 2026 in “Journal of the American Chemical Society” This study designed a new bifunctional protein that successfully degrades the cancer target BCL-xL in cells, inducing apoptosis with high binding success rates.
This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.
3 citations
,
October 2025 in “Cancer” This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.